Advertisement
UK markets open in 2 hours 14 minutes
  • NIKKEI 225

    39,200.29
    +412.91 (+1.06%)
     
  • HANG SENG

    19,650.18
    +96.57 (+0.49%)
     
  • CRUDE OIL

    80.09
    +0.03 (+0.04%)
     
  • GOLD FUTURES

    2,440.20
    +22.80 (+0.94%)
     
  • DOW

    40,003.59
    +134.19 (+0.34%)
     
  • Bitcoin GBP

    52,757.25
    -32.26 (-0.06%)
     
  • CMC Crypto 200

    1,361.76
    -12.08 (-0.88%)
     
  • NASDAQ Composite

    16,685.97
    -12.33 (-0.07%)
     
  • UK FTSE All Share

    4,584.23
    -10.47 (-0.23%)
     

Scotts Miracle-Gro Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Scotts Miracle-Gro (NYSE:SMG) Second Quarter 2024 Results

Key Financial Results

  • Revenue: US$1.53b (flat on 2Q 2023).

  • Net income: US$157.5m (up 44% from 2Q 2023).

  • Profit margin: 10% (up from 7.1% in 2Q 2023).

  • EPS: US$2.77 (up from US$1.95 in 2Q 2023).

earnings-and-revenue-growth
earnings-and-revenue-growth

All figures shown in the chart above are for the trailing 12 month (TTM) period

Scotts Miracle-Gro Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 1.0%. Earnings per share (EPS) missed analyst estimates by 18%.

Looking ahead, revenue is forecast to grow 3.6% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Chemicals industry in the US.

ADVERTISEMENT

Performance of the American Chemicals industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

It's necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with Scotts Miracle-Gro (at least 1 which is a bit unpleasant), and understanding these should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.